Company News

ProMIS Neurosciences Reminds Shareholders of June 25th Voting Cut-Off for Upcoming Annual General Meeting

By | News

News Release ProMIS Neurosciences Reminds Shareholders of June 25th Voting Cut-Off for Upcoming Annual General Meeting TORONTO, ONTARIO and CAMBRIDGE, MA – June 20, 2018 – ProMIS Neurosciences Inc. (the “Corporation”) (TSX: PMN.TO) (OTCQB: ARFXF) would like to remind shareholders they have until 9:00 am (Toronto Time) on Monday June…

Read More

ProMIS Neurosciences Initiates Manufacturing of PMN310, its Lead Therapeutic Antibody for Treatment of Alzheimer’s Disease

By | News

ProMIS Neurosciences Initiates Manufacturing of PMN310, its Lead Therapeutic Antibody for Treatment of Alzheimer’s Disease Program is on track for clinical trial start in H2 2019 TORONTO, ONTARIO and CAMBRIDGE, MA – June 12, 2018 – ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of precision…

Read More

ProMIS Neurosciences Announces First Quarter 2018 Results

By | News

ProMIS Neurosciences Announces First Quarter 2018 Results TORONTO, ONTARIO and CAMBRIDGE, MA –May 11, 2018 – ProMIS Neurosciences Inc. (“ProMIS” or the “Company”), a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced its operational and financial results for the three months ended March…

Read More

PROMIS NEUROSCIENCES CLOSES $7.2 MILLION PRIVATE PLACEMENT

By | News

PROMIS NEUROSCIENCES CLOSES $7.2 MILLION PRIVATE PLACEMENT TORONTO, Ontario and CAMBRIDGE, Massachusetts–May 1, 2018– ProMIS Neurosciences Inc. (TSX:PMN; OTCQB:ARFXF) is pleased to announce that it closed yesterday  a private placement of 19,306,668 Units at the price of CDN$0.375 per Unit for gross proceeds of approximately CDN$ 7,240,000. “We are pleased to…

Read More